Zydus Lifesciences Limited reported a steady performance for the quarter ended June 30, 2025, with growth across key geographies and strong contributions from innovation-driven initiatives. The pharmaceutical major posted revenue from operations of Rs. 65,737 million, marking a 6% increase year-on-year and a marginal 0.7% rise from the previous quarter. Net profit stood at Rs. 14,668 million, up 3% from the same quarter last year and a robust 25.3% higher than Q4 FY25.
Earnings before interest, tax, depreciation, and amortisation (EBITDA) came in at Rs. 20,885 million, translating into a margin of 31.8%. While this was slightly lower than last year’s 33.6%, it represented an improvement from the previous quarter’s 32.6%. Research and development expenditure reached Rs. 4,856 million, or 7.4% of revenues, as the company continued to invest heavily in its innovation pipeline. Capital expenditure for the quarter was Rs. 4,020 million.
The India business, comprising both formulations and consumer wellness, generated Rs. 23,744 million, up 6% year-on-year and contributing 37% of total revenues. Prescription formulations brought in Rs. 15,195 million, an 8% rise driven by strong performance in chronic therapy segments such as oncology, cardiology, respiratory care, anti-infectives, and pain management. The consumer wellness portfolio recorded Rs. 8,549 million in sales, up 2%, with double-digit growth in non-seasonal brands. Organised trade channels showed healthy gains, and e-commerce contributed 14.5% to wellness revenues.
The US formulations business remained the largest contributor, delivering Rs. 31,817 million in revenue, a 2.9% rise over the previous year and accounting for nearly half of consolidated sales. During the quarter, the company launched three new products in the US market, filed three abbreviated new drug applications (ANDAs), and secured six product approvals, including two tentative approvals. International formulations sales surged 37% year-on-year to Rs. 7,265 million, reflecting expanding footprints in emerging markets. The active pharmaceutical ingredients (API) segment posted revenues of Rs. 1,575 million, an 11.3% increase, while the alliances and others segment declined 28% to Rs. 269 million.
Operationally, Zydus received USFDA Establishment Inspection Reports for its API facilities in Ankleshwar and Dabhasa after inspections earlier this year, underscoring its regulatory compliance. Innovation remained a key focus area, with notable developments including the start of Phase II(b) trials in the US for Usnoflast, a novel NLRP3 inflammasome inhibitor for amyotrophic lateral sclerosis (ALS), which also received USFDA Fast Track and Orphan Drug designation. The company also obtained DCGI marketing approval for its biosimilars Rituximab and Aflibercept.
Looking ahead, Managing Director Dr. Sharvil Patel said the results reflect “disciplined execution” and are aligned with the company’s FY26 aspirations. He added that ongoing investments in innovation and market expansion are expected to open new avenues for sustainable growth in the coming quarters.
